Recordati
Italian multinational pharmaceutical group specializing in rare diseases, specialty medicines, and selected primary-care treatments.
Last updated October 6, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Recordati is an Italian pharmaceutical group headquartered in Milan and listed on Euronext Milan. Founded in 1926 by Giovanni Recordati, the company developed from an Italian medicines business into an international healthcare organization with activities spanning research, development, manufacturing, licensing, commercialization, and distribution. Its portfolio combines medicines for rare and disabling diseases with specialty products and selected treatments used in broader primary-care settings. The group’s strategic identity has increasingly been shaped by its rare-disease business. This area typically involves highly specialized medicines, concentrated patient populations, complex diagnosis and treatment pathways, and the need for dedicated medical and commercial capabilities. Alongside rare diseases, Recordati maintains specialty-care activities and a broader portfolio of established prescription medicines. The combination gives the company a mix of focused high-specialty products and more mature pharmaceutical franchises. Recordati operates internationally through its own commercial organizations and partnerships. Its markets extend across Europe and other regions, including the Americas, Asia, Africa, and Oceania. International expansion has been supported by product licensing, acquisitions, geographic commercialization, and the development of manufacturing and regulatory capabilities. The group presents itself as a life-sciences company seeking to increase access to medicines that can materially improve or change patients’ lives. Recordati remains a publicly traded company while operating as an international pharmaceutical group. Its public corporate materials emphasize medicines for rare diseases and specialty conditions, together with a long-standing history in pharmaceutical manufacturing and commercialization. Product availability differs by country because approvals, indications, brand ownership, and distribution arrangements are jurisdiction-specific. Accordingly, Recordati should be understood as a corporate pharmaceutical brand and group rather than as a single consumer-facing medicine brand.
History
Recordati was established in Italy in 1926 by Giovanni Recordati. Its origins lie in the development and commercialization of pharmaceutical products, from which it expanded into a broader industrial and international healthcare group. Over time, the company built capabilities across pharmaceutical research, manufacturing, regulatory affairs, licensing, and commercial operations. The group’s growth involved the development of branded medicines as well as the international licensing and commercialization of products. This model allowed Recordati to serve multiple therapeutic areas and geographic markets while maintaining a focus on prescription pharmaceuticals. Its international reach broadened beyond Italy into Europe and other world regions through subsidiaries, partnerships, and distribution networks. A major long-term direction has been the strengthening of rare-disease and specialty-care activities. These areas require specialized scientific knowledge, focused patient identification, regulatory expertise, and targeted market access work. Recordati’s corporate materials describe the company as being particularly active in medicines that address rare or serious conditions, while also retaining established products used in wider medical practice. Recordati became a listed company and has continued to operate under the Recordati name as an international pharmaceutical enterprise. The company’s public-market identity is associated with the REC ticker on Euronext Milan. Its ownership and strategic structure have also been affected by investment activity, including a voluntary public tender offer launched by Respighi BidCo S.p.A.; the available reference material confirms the existence of related documentation but does not establish a complete transaction history. In its current positioning, Recordati presents itself as a life-enhancing and life-changing medicines company. Its business spans the discovery or acquisition of pharmaceutical assets, development and regulatory work, manufacturing, and commercialization. Because its portfolio and marketing rights vary by territory, individual brands and indications must be checked against local regulatory and company information. The enduring themes of the group’s history are Italian pharmaceutical origins, international expansion, specialty and rare-disease focus, and the operation of a diversified prescription-medicine platform.
- 1926
Recordati is founded in Italy
[1]Giovanni Recordati establishes the pharmaceutical business that later develops into the Recordati group.
International pharmaceutical expansion
[1]Recordati expands its activities beyond Italy through international commercial operations, partnerships, licensing, and pharmaceutical manufacturing capabilities.
Greater emphasis on rare diseases and specialty medicines
[1]The company increasingly positions rare-disease and specialty-care medicines as central elements of its international pharmaceutical strategy.
Public tender-offer documentation is published
[1]Recordati’s official website provides access to documents relating to a voluntary public tender offer launched by Respighi BidCo S.p.A.
Products and positioning
An international pharmaceutical group combining rare-disease medicines, specialty treatments, and selected established prescription products.
Rare diseases
Rare-disease medicines
A central Recordati business area consisting of prescription treatments for uncommon and often serious conditions. These products generally require specialized diagnosis, focused medical education, and targeted patient-access programs. Specific brands, indications, and commercial rights vary by country.
Specialty pharmaceuticals
Specialty-care medicines
Recordati’s specialty portfolio addresses conditions requiring focused clinical knowledge or specialist involvement. The group combines internally developed, acquired, licensed, and commercialized medicines, with availability and approved uses determined by local regulators.
Primary care pharmaceuticals
Established prescription medicines
Alongside its higher-specialty businesses, Recordati maintains established prescription products used in broader medical practice. These medicines support the group’s diversified pharmaceutical model and international commercial presence.
Brand decisions
- Participation in a public tender-offer processM&A
Background
Recordati’s official website contains documents concerning a voluntary public tender offer launched by Respighi BidCo S.p.A.
Action taken
The company made tender-offer-related documentation available through its corporate website.
Aftermath
The supplied reference material does not establish the final outcome, ownership consequences, or financial terms of the offer.
Recent events
Recordati corporate website highlights public tender-offer documentation[1]
M&A
Recordati’s official home page directs stakeholders to documents concerning a voluntary public tender offer launched by Respighi BidCo S.p.A. The page does not, by itself, provide enough information here to establish the offer’s final outcome or transaction terms.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/recordati · Editorial policy · How profiles are compiled